Generic Drug Prices Are Dropping, but Who Is This Really Benefiting?
It seems that overall drug spending is still on the rise because of the skyrocketing price of new, brand-name drugs.
Charles Ornstein & Katie Thomas
Charles Ornstein is a senior reporter for ProPublica covering health care and the pharmaceutical industry.
Corporate Incentives Make Insurers Favor Pushing Brand-Name Drugs Over Cheaper Generics
Out of public view, corporations are cutting deals that give consumers little choice but to buy brand-name drugs—and sometimes pay more at the pharmacy counter than they would for generics.
Behind Pharmaceutical Companies' Money-Back Guarantees
Drugmakers are increasingly agreeing to refund money if patients don't respond to medications as expected.